First-line treatment for advanced ovarian cancer: Paclitaxel, platinum and the evidence

British Journal of Cancer

Volumn 87, Issue 8, 2002, Pages 815-824

  Sandercock, J ^a   Parmar, M K B ^b   Torri, V ^c   Qian, W ^b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b MRC CLINICAL TRIALS UNIT   (United Kingdom)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Heterogeneity; Ovarian cancer; Paclitaxel; Platinum

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL; PLATINUM;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MONOTHERAPY; OVARY CANCER; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CYCLOPHOSPHAMIDE; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037037385     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600567     Document Type: Review

References (49)

1. Adams M, A'Hern RP, Calvert AH, Carmichael J, Clark PI, Coleman RE, Earl HM, Gallagher CJ, Ganesan TS, Gore ME, Graham JD, Harper PG, Jayson GC, Kaye SB, Ledermann JA, Osborne RJ, Perren TJ, Poole CJ, Radford JA, Rustin GJ, Slevin ML, Smyth JF, Thomas H, Wilkinson PM (1998) Chemotherapy for ovarian cancer - A consensus statement on standard practice. Br J Cancer 78: 1404-1406
2. Adams M, Kerby IJ, Rocker I, Evans A, Johansen K, Franks CR (1989) A comparison of toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncol 28: 57-60
3. Advanced Ovarian Cancer Trialists Group (1998) Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomised trials. Br J Cancer 78: 1479-1487
4. Athanassiou A, Varthalitis J, Tsavaris N, Dimitriadis M, Moutzouridis G (1997) Superiority of carboplatin monochemotherapy over carboplatin-based polychemotherapy in ovarian cancer. Eur J Gynaecol Oncol 18: 420-425
5. Bolis G, Favalli G, Danese S, Zanaboni F, Mangili G, Scarabelli C, Tateo S, Valsecchi MG, Scarfone G, Richiardi G, Frigerio L, Melpignano M, Villa A, Parazzini F (1997) Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer. J Clin Oncol 15: 1938-1944
6. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756
7. Cohen CJ, Goldberg JD, Holland JF, Bruckner HW, Deppe G, Gusberg SB, Wallach RC, Kabakow B, Rodin JI (1983) Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO stages III and IV) as measured by surgical end-staging (second-look) operation. Am J Obstet Gynecol 145: 955-965
8. Colombo N on behalf of the ICON Collaborators (2000) Randomised trial of paclitaxel (PTX) and carboplatin (CBDCA) versus a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin & cisplatin): The Third International Collaborative Ovarian Neoplasm Study (ICON3). Proc Am Soc Clin Oncol 19: 379a (abstract 1500)
9. du Bois A, Lueck HJ, Meier W, Moebus V, Costa SD, Bauknecht T, Richter B, Warm M, Schroeder W, Olbricht S, Nitz U, Jackisch C (1999) Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial. Proc Am Soc Clin Oncol 18: 356a (abstract 1374)
10. Gennatas C, Mouratidou D, Andreadis C (2000) A phase III trial comparing taxol and cisplatin versus cyclophosphamide and cisplatin in advanced ovarian cancer: A preliminary report. Proc Am Soc Clin Oncol 20: 404a (abstract 1600)
11. GICOG (1992) Long-term results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide with cisplatin, cyclophosphamide and adriamycin in advanced ovarian cancer. Gynecol Oncol 45: 115-117
12. Gore M, A'hern R, Swenerton K (1997) Good manners for the pharmaceutical industry. Lancet 350: 370
13. Harper P on behalf of the ICON Collaborators (1999) A randomised comparison of paclitaxel (T) and carboplatin (J) versus a control arm of single agent carboplatin (J) or CAP (cyclophosphamide, doxorubicin and cisplatin): 2075 Patients Randomised Into the 3rd International Collaborative Ovarian Neoplasm Study (ICON3). Proc Am Soc Clin Oncol 18: 356a (abstract 1375)
14. ICON Collaborators (1998) ICON2: A randomised trial of single agent carboplatin against the 3-drug combination of CAP (cyclophosphamide, doxorubicin and cisplatin) in women with ovarian cancer. Lancet 352: 1571-1576
15. ICON Collaborators (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, cisplatin in women with ovarian cancer: The ICON3 randomised trial. The Lancet 360: 505-515
16. Kaye SB, Paul J, Cassidy J, Lewis CR, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, Davis JA, Reed NS, Crawford SM, MacLean A, Parkin D, Sarkar TK, Kennedy J, Symonds RP for the Scottish Gynaecology Cancer Trials Group (1996) Mature results of a randomised trial of two doses of cisplatin for the treatment of ovarian cancer. J Clin Oncol 14: 2113-2119
17. Lister-Sharp D, McDonagh M, Saeed Khan K, Kleijnen J (2000) A systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technology Assessment 4(17)
18. Mangioni C, Bolis G, Pecorelli S, Bragman K, Epis A, Favalli G, Gambine A, Landoni F, Presti M, Torri W, Vassena L, Zanabon F, Marsoni S (1989) Randomised trial in advanced ovarian cancer comparing cisplatin and carboplatin. J Nat Cancer Inst 81: 1464-1471
19. Markman M, Bundy B, Benda J, Alberts D, Wadler S, Fowler J, Clark-Pearson D, Carson LF for the Gynecologic Oncology Group (1998) Randomized phase 3 study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer (OC): An Intergroup trial (GOG, SWOG, ECOG). Proc Am Soc Clin Oncol 17: 361a (abstract 1392)
20. Markman M, Bundy B, Benda J, Alberts D, Fowler J, Clark-Pearson D, Carson L, Wadler S, Sickel J (2001) Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin cisplatin in small-volume stage III ovarian carcinoma: And intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001-1007
21. Marth C, Trope C, Vergote IB, Kristensen GB (1998) Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer. Eur J Cancer 34: 1175-1180
22. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Look KY, Partridge EE et al (1993) A phase III trial comparing cisplatin/cytoxan and cisplatin/paclitaxel in advanced ovarian cancer. Proc Am Soc Clin Oncol 12: 255a (abstract 808)
23. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Look KY, Partridge EE, Davidson M (1995) Taxol and cisplatin (TP) improves outcome in advanced ovarian cancer (AOC) as compared to cytoxan and cisplatin (CP). Proc Am Soc Clin Oncol 14: (abstract 771)
24. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson MD (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
25. Muggia FM, Braly PS, Brady MF, Sutton G, Copeland LJ, Lentz SL, Alvarez RD, Kucera PR, Small J (1997) Phase III of cisplatin (P) or paclitaxel (T), versus their combination in suboptimal stage III and IV epithelial ovarian cancer (EOC): Gynecologic Oncology Group (GOG) study number 132. Proc Am Soc Clin Oncol 16: (abstract 1257)
26. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 18: 106-115
27. National Cancer Guidance Steering Group (1999) Improving Outcomes in Gynaecological Cancers: The Research Evidence. London: NHS Executive, Department of Health
28. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Heintz AP, van Lent M, Trimbos JB, Bouma J, Vermorken JB (1987) Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 5: 1157-1168
29. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Sessa C, de Swart CAM, Hirsch FR, Lund B, van Houwelingen HC (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084-3092
30. Ovarian Cancer Meta-analysis Project (1991) Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis. J Clin Oncol 9: 1668-1674
31. Ozols RF, Bundy BN, Fowler J, Clarke-Pearson D, Mannel R, Hartenbach EM, Baergen R (1999) Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optinal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG-158). Proc Am Soc Clin Oncol 18: 356a (abstract 1373)
32. Parmar MKB, Sandercock J (1996) Chemotherapy for ovarian cancer. N Engl J Med 334: 1268-1269
33. Piccart MJ, Bertelsen K, Stuart G, James K, Cassidy J, Kaye S, Hoctin Boes G, Timmers P, Roy JA, Pecorelli S (1997) Is cisplatin-paclitaxel the standard first-line treatment of advanced ovarian cancer? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc Am Soc Clin Oncol 16: (abstract 1258)
34. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Tropé C, Nardi M, Kaern J, Tumulo S, Timmers P, Roy J-A, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S (2000) Randomized Intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: 3 Year results. J Nat Cancer Inst 92: 699-708
35. Rankin EM, Mill L, Kaye SB, Atkinson R, Cassidy L, Cordiner J, Cruickshank D, Davis J, Duncan ID, Fullerton W, Habeshaw T, Kennedy J, Kennedy R, Kitchener H, MacLean A, Paul J, Reed N, Sarker T, Soukop M, Swapp GH, Symonds RP (1992) A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 65: 275-281
36. Richter P, Krafft W, Muller U, Bruckmann D, Homann S, Konig EM, Lotze P, Morack G, Neubert S, Noschel H et al (1990) Effectiveness of cisplatin alone and in combination within the scope of primary therapy of ovarian cancer. Results of a prospective multicenter study]. [German]. Zentralblatt fur Gynakologie 112: 421-429
37. Sandercock J, Parmar MKB, Torri V (1998) First-line chemotherapy for advanced ovarian cancer: Paclitaxel, cisplatin and the evidence. Br J Cancer 78: 1471-1478
38. Sandercock J (1998) The Role of Platinum Dose and Dose Intensity in Chemotherapy for Advanced Ovarian Cancer [dissertation]. Greenwich: University of Greenwich
39. Simsek T, Kaya H, Zorlu G, Trak B, Uner M, Ozbilim G et al (1999) The effectivity of 'paclitaxel-cisplatin' versus 'cislatin-cyclophosphamide' in the treatment of advanced stage malign epithelial ovarian tumors in which optimal cytoreductive surgery were performed. Jinekoloji ve Ovstetrik Dergisi 13(4): 215-218
40. Skarlos DV, Aravantinos G, Kosmidis P, Pavlidis N, Gennatas K, Beer M, Mylonakis N, Makrantonakis P, Klouvas G, Karpathios S, Linardou H, Konstantaras C, Fountzilas G (1996) Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: A Hellenic co-operative oncology group study. Eur J Cancer 32A: 421-428
41. Stuart G, Bertelsen K, Mangioni C, Tropé C, James K, Cassidy J, Kaye S, Timmers P, Roy JA, Piccart MJ (1998) Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first-line treatment of advanced ovarian cancer: Mature results of the EORTCGCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial. Proc Am Soc Clin Oncol 17: 361a (abstract 1394)
42. Taxanes (Ovarian Cancer) (2002): Update Health Technology Assessment (in press)
43. Taylor AE, Wiltshaw E, Gore M, Fryatt I, Fisher C (1994) Long-term follow-up of the first randomised study of cisplatin versus carboplatin for advanced epithelial ovarian cancer. J Clin Oncol 12: 2066-2070
44. Thompson SG, Sharp SJ (1999) Explaining heterogeneity in meta-analysis: A comparison of methods. Stat Med 18: 2693-2708
45. Tomirotti M, Perrone S, Gie P, Canaletti R, Carpi A, Biasoli R, Lombardi F, Giovanninetti A, Mensi F, Villa S (1988) Cisplatin (P) versus cyclophosphamide, adriamycin and cisplatin (CAP) for stage III-IV epithelial ovarian carcinoma: A prospective randomized trial. Tumori 74: 573-577
46. Torri V, Harper PG, Colombo N, Sandercock J, Parmar MKB (2000) Paclitaxel and cisplatin in ovarian cancer. J Clin Oncol 18(11): 2349-2351
47. Trope C, Vergote I (1999) Improved survival with paclitaxel-cisplatin compared with cyclophosphamide cisplatin in advanced ovarian cancer after a median follow-up of 39 months: Update of the EORTC, NOCOVA, NCIC, Scottish Intergroup study. Int J Gynecol Cancer 9(Suppl 1): S57
48. Wiltshaw E, Evans B, Rustin G, Gilbey E, Baker J, Barker G (1986) A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol 4: 722-729
49. Wolf C, Schonborn J, Sehouli J, Kuhndel K, Dietrich K, Riess H, Kettner H, Lichtenegger W (1999) Preliminary results of a randomized trial: Paclitaxel/carboplatin vs cyclophosphamide/carboplatin in the first line treatment of advanced ovarian cancer. Int J Gynecol Cancer 9(supplement 1): S12